

April 29, 2015

CBD MED RESEARCH CORP. ("CBD" or the "Company")
TSX.V NEX Symbol: CBM.H

CBD MED Research Corp. announces Life Science and Medical Technology Advisory Board

April 29, 2015: CBD MED Research Corp.: The company is pleased to announce the formation and newly appointed members of the corporate advisory board. www.cbdmedresearch.com

Bill Cheliak, Ph.D., has more than 20 years of experience in the life sciences sector including founding and executive roles at 7 life-science companies, two of which were publicly traded. Experience with several exits, one to Novartis, and many deals including with Pfizer, BMS, Astellas and Genentech.

Roman V. Dvorak, M.D., Ph.D., has 15 years Clinical Director experience in clinical development, regulatory guidance and business development. Currently Senior Director, Clinical Development Vivus Inc., Mountain View CA., specializing in metabolic disease and development of diabetic/obesity disorders. He has had senior roles with Knoll Pharmaceutical, J&J, Pfizer Inc., Terica Inc. (acquired by Epsen 2008), and CeaurTec Medical Inc.

Charles P. Garrison M.D. has 38 years of experience as an American Board Certified Pathologist in Anatomic and Clinical Pathology. He has been involved in founding and selling several medical laboratory businesses including a cytogenetic laboratory, a tissue bank and a sperm bank, and has been involved in running a histopathology reference laboratory, a cell bank for big pharma, and a telemedicine service company.

Gianni F. Maddalozzo, Ph.D. FACSM is the Director of the Bone Research Laboratory at Oregon State University. During the past ten years he has headed research programs focused on musculoskeletal health and aging. He has published extensive findings on the therapeutic benefits of a wide range including whole body vibration technology, bone density, muscular strength, neuropathic pain of the feet, hormone replacement, nutrition and exercise. Dr. Maddalozzo is an active member of the American College of Sports Medicine.

Brian T. Wagner, President NHP Consulting Inc. - Brian founded NHP in 2004. NHP has succeeded in assisting hundreds of companies World Wide launch their

natural Health Products in Canada. Brian and his team of experts provide expertise in highly regulated environments including biotechnology, pharmaceutical and natural health care. Brian is active with the Canada Health Food Association and played key roles in product licensing regulation and quality assurance compliance.

John McCluskey - John is Director of NHP Regulatory Operations. He has 16 years of experience in highly regulated environments including Biotechnology, Pharmaceutical and Natural Health Care / Dietary Supplements. For ten years he has held various management roles in Quality Assurance and Regulatory Affairs for brand names in Canada and the USA. His experience also includes implementing quality systems and launching brand names to ensure compliance with Health Canada and the US Food and Drug Administration (FDA). His experience includes auditing manufacturers and ensuring all tasks and responsibilities adhere to (c) GMP standards.

The company and its advisory board are currently focused on due diligence reviews and identification of commercial business opportunities in the Life Science, Medical Device and Digital Health Technology sector.

www.cbdmedresearch.com

On behalf of the Board of Directors,

CBD Med Research Corp.

"Gary F. Zak"
President, CEO

Email: gzak1@shaw.ca
Tel: 604-802-7551

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

We seek Safe Harbor.

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, including the likelihood of commercial mining and possible future financings are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such

statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include unsuccessful business, changes in forecast prices, changes in the availability of funding for proposed business plans, unanticipated changes in key management personnel and general economic conditions. Accordingly the actual events may differ materially from those projected in the forward-looking statements. For more information on the Company and the risks and challenges of its business, investors should review the Company's annual filings that are available at www.sedar.com.